Targeting Tissue Perfusion and Lower MAP in Septic Shock Did Not Improve 30‑Day Perfusion-Free Survival: Results from the TARTARE-2S Randomized Trial
Highlights
– In TARTARE-2S (n=219), a protocol targeting tissue perfusion (capillary refill time, peripheral temperature, lactate) and allowing MAP 50–65 mm Hg produced no improvement in days alive with normalized lactate and vasopressor-free at 30 days compared with guideline-based MAP-guided standard care.
– Median days alive and free of vasopressors with normal lactate were 23 versus 22 days (difference 0.59 days; 95% CI, −3 to 4), and 30‑day mortality was similar (24.7% vs 27.8%).
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.